ClinicalTrials.gg
Active, not recruitingNCT07217184Updated Jun 25, 2026Results posted

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

A Phase 1/2 interventional study of Belantamab mafodotin and Isatuximab in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 19 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Jul 2021, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
30th of 49
30 · median 50
Started
2021
with 10 others
Phase 1/2
17 of 49
3 open now
Primary completion
2025-04
later than 8 of 34 live
Registered
42nd of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 30th largest by enrollment, is one of 11 that started in 2021, is one of 17 in phase 1/2, reaches primary completion later than 8 of the 34 other live ones, and was the 42nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Belantamab Mafodotin
  • Isatuximab
  • GSK2857916
  • Multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years of age inclusive or older, at the time of signing the .
  • Participants must have or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG.
  • Participants having at least 3 prior lines of prior anti-myeloma treatments including an immunomodulating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.
  • Participants with a history of stem cell transplant are eligible for study participation when, transplant was >100 days prior to study enrolment and with no active infection(s).
  • Participants with (ECOG) performance status of 0-1, unless ECOG less than equal to (\<=)2 is due solely to skeletal complications and/or skeletal pain due to MM.
  • Participants with defined as at least one of the following: Serum M-protein greater than equal to (>=)0.5 gram per deciliter (>=5 gram per liter) or Urine M-protein >=200 milligrams (mg) per 24 hours or Serum free light chain (FLC) assay: Involved FLC level >=10 mg per deciliter (>=100 mg per Liter) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participants who have tested positive for core antibody (HBcAb) can be enrolled if the following criteria are met: Serology result HBcAb+, Hepatitis B surface antigen (HBsAg)-; HBV deoxyribonucleic acid (DNA) undetectable during screening.
  • Participants who are currently receiving physiological doses oral (\<10 mg/day), inhaled steroids or ophthalmological steroids.

Exclusion criteria

Exclusion Criteria:

  • Participants with current corneal epithelial disease except mild punctate keratopathy.
  • Participants with evidence of cardiovascular risk.
  • Participants with known immediate or delayed reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other mAb.
  • Participants with active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma therapy within \<14 days.
  • Participants with prior radiotherapy within 2 weeks of start of study therapy.
  • Participants with prior transplant are prohibited.
  • Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
  • Participants with any major surgery (other than bone-stabilizing surgery) within the last 30 days.
  • Participants with prior treatment with an agent within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is shorter.
  • Participants with >=grade 3 toxicity considered related to prior check-point inhibitors and that led to treatment discontinuation.
  • Participants who have received transfusion of blood products within 2 weeks before the first dose of study drug.
  • Participants must not receive within 30 days prior to first dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in any sub-study arm of the platform trial and for at least 70 days following last study treatment.
  • Participants with presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM.
  • Participants with known (HIV) infection, unless the participant can meet all criteria: a) established anti-retroviral therapy for at least 4 weeks and HIV viral load\<400 copies/milliliter (mL) b) cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >= 350 cells/microliter (µL) c) No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months in which case the participant would be eligible for CE Phase only. For participants receiving nirogacestat, HIV drugs that are strong Cytochrome P450 3A4 () inhibitors are prohibited. HIV drugs that are moderate CYP3A4 inhibitors, while permitted, should be co-administered with caution and must be accompanied by nirogacestat dose modifications.
  • Participants with Severe hypersensitivity to Isatuximab-irfc or to any of its .
  • Participants with prior treatment with other anti-CD38 monoclonal antibody within 6 months of the first dose of study drug treatment.
  • Participants with known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Belantamab mafodotin + Isatuximab

    Drug: Belantamab mafodotin · Drug: Isatuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT)

    Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as Grade 3-5 febrile neutropenia and thrombocytopenia with bleeding. Non-hematologic criteria, excluding corneal toxicity, comprise Grade 3-5 toxicities, with exceptions for manageable nausea, vomiting, or diarrhea, controlled Grade 3 hypertension, and events linked to disease progression. Tumor lysis syndrome (TLS) of Grade 3 or 4, successfully managed within 7 days without end-organ damage, is considered. Corneal toxicity, assessed by the GSK corneal grading scale at Grade 4, is a DLT. Other organ-specific toxicities, notably liver toxicity meeting GSK stopping criteria, also qualify as DLT severity was graded using National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0.

    Time frame: Up to 28 days

  2. DE Phase: Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 194 weeks

  3. DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline

    Blood samples were collected for the analysis of hematology parameters. The laboratory parameters were graded according to CTCAE v 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. WBC: White blood cells.

    Time frame: Baseline (Day 1) and up to approximately 194 weeks

  4. DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline

    Blood samples were collected for the analysis of chemistry parameters. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. BLD : Blood lactate dehydrogenase, CPK: Creatine Kinase.

    Time frame: Baseline (Day 1) and up to approximately 194 weeks

  5. Cohort Expansion (CE) Phase: Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 194 weeks

Secondary outcomes

  1. DE Phase: Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 194 weeks

  2. CE Phase: Clinical Benefit Rate (CBR)

    Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

    Time frame: Up to approximately 194 weeks

  3. DE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)

    Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] were assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 194 weeks

  4. CE Phase: Percentage of Participants Achieving SCR, CR, VGPR and PR

    Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] was assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 194 weeks

  5. DE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.

    Time frame: Predose (PD), end of infusion (EOI), and 2-hour and 24-hour postdose on Cycle 1 Day 1; predose on C1D8, C1D15 and C1D22, anytime samples on C1D8 and C1D22; predose and EOI on Day 1 of Cycles 2, 4, 6, 9 and 12; and end of treatment (~194 weeks).

  6. CE Phase: Plasma Concentration of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)

    Blood samples were to be collected for PK analysis of Belantamab Mafodotin Antibody-Drug Conjugate (ADC).

    Time frame: Up to approximately 194 weeks

  7. DE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody

    Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.

    Time frame: Predose, end of infusion (EOI), and 2-hour and 24-hour on Cycle 1 Day 1; predose and anytime samples on Cycle 1 Days 8 and 22; predose on Cycle 1 Day 15; predose and EOI on Day 1 of Cycles 2, 4, 6, 9, and 12; and end of treatment (~194 weeks).

  8. CE Phase: Plasma Concentration of Belantamab Mafodotin Plasma Total Antibody

    Blood samples were to be collected for PK analysis of Belantamab mafodotin plasma total antibody.

    Time frame: Up to approximately 194 weeks

  9. DE Phase: Plasma Concentration of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

    Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).

    Time frame: Predose, end of infusion (EOI), and 2-hour and 24-hour postdose on Cycle 1 Day 1; predose on Cycle 1 Days 8, 15 and 22, anytime samples on C1D8 and C1D22 ; predose and EOI on Day 1 of Cycles 2, 4, 6, 9 and 12; and end of treatment (~194 weeks).

  10. CE Phase: Plasma Concentration of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

    Blood samples were to be collected for PK analysis of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

    Time frame: Up to approximately 194 weeks

  11. DE Phase: Isatuximab Concentration When Administered in Combination With Belantamab Mafodotin

    Blood samples were collected for PK analysis of Isatuximab when administered intravenously in combination with belantamab mafodotin.

    Time frame: Predose on Cycle (C)1 Day (D)1, D8, D15 and D22; predose on C2D1 and C2D15; predose on C3D1 and C3D15; predose on C4D1 and C4D15; predose on C5D1, C6D1, C7D1, C8D1, C9D1 and C10D1; and end of treatment (~194 weeks).

  12. CE Phase: Isatuximab Concentration When Administered in Combination With Belantamab Mafodotin

    Blood samples were planned to be collected for PK analysis of isatuximab when administered intravenously in combination with belantamab mafodotin.

    Time frame: Up to approximately 194 weeks

  13. DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to approximately 194 weeks

  14. CE Phase: Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to approximately 194 weeks

  15. DE Phase: Titer of ADAs Against Belantamab Mafodotin

    Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to approximately 194 weeks

  16. CE Phase: Titer of ADAs Against Belantamab Mafodotin

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to approximately 194 weeks

  17. DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI, whether serious or non serious were collected.

    Time frame: Up to approximately 194 weeks

  18. CE Phase: Number of Participants With AESI

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI, whether serious or non serious, were to be collected.

    Time frame: Up to approximately 194 weeks

  19. DE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade

    The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade v 5.0.

    Time frame: Up to approximately 194 weeks

  20. CE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade

    The corneal events were planned to be graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results were to be presented for number of participants with any corneal events by maximum grade as per CTCAE grade v5.0.

    Time frame: Up to approximately 194 weeks

  21. CE Phase: Progression-free Survival (PFS)

    PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.

    Time frame: Up to approximately 194 weeks

  22. CE Phase: Duration of Response (DoR)

    DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.

    Time frame: Up to approximately 194 weeks

  23. CE Phase: Time to Response (TTR)

    TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).

    Time frame: Up to approximately 194 weeks

  24. CE Phase: Overall Survival (OS)

    OS is defined as the time from randomization until death due to any cause.

    Time frame: Up to approximately 194 weeks

  25. CE Phase: Number of Participants With AEs and SAEs

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 194 weeks

  26. CE Phase: Number of Participants With AEs Leading to Discontinuation

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to discontinuation were to be evaluated.

    Time frame: Up to approximately 194 weeks

  27. CE Phase: Number of Participants With Dose Reduction or Delay

    Number of participants with dose reduction or delay were to be evaluated.

    Time frame: Up to approximately 194 weeks

  28. CE Phase: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters

    Blood samples were to be collected for the analysis of hematology parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3: severe or medically significant; Grade 4 (G4): Life-threatening consequences; Grade 5 (G5): Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

    Time frame: Up to approximately 194 weeks

  29. CE Phase: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters

    Blood samples were to be collected for the analysis of chemistry parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. G1: mild; G2: moderate; G3: severe or medically significant; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

    Time frame: Up to approximately 194 weeks

07

Results

Posted Jun 25, 2026

Participant flow

This is a sub-study of the master study NCT04126200. The study was planned to include two phases - Dose Escalation (DE) and Cohort Expansion (CE) and no participants from this sub study were enrolled in CE phase as CE Phase was not initiated due to business strategic reason.

Participant flow — Overall Study
Milestone1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Started101010
Dose limiting toxicity (dlt) evaluable population788
Completed978
Not completed132
Withdrew: Physician decision010
Withdrew: Withdrawal by subject110
Withdrew: Ongoing at the time of analysis012

Outcome measures

PrimaryDose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT)

Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as Grade 3-5 febrile neutropenia and thrombocytopenia with bleeding. Non-hematologic criteria, excluding corneal toxicity, comprise Grade 3-5 toxicities, with exceptions for manageable nausea, vomiting, or diarrhea, controlled Grade 3 hypertension, and events linked to disease progression. Tumor lysis syndrome (TLS) of Grade 3 or 4, successfully managed within 7 days without end-organ damage, is considered. Corneal toxicity, assessed by the GSK corneal grading scale at Grade 4, is a DLT. Other organ-specific toxicities, notably liver toxicity meeting GSK stopping criteria, also qualify as DLT severity was graded using National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT)
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT)201
PrimaryDE Phase: Number of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 194 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Adverse Events (AEs)
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
DE Phase: Number of Participants With Adverse Events (AEs)101010
PrimaryDE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline

Blood samples were collected for the analysis of hematology parameters. The laboratory parameters were graded according to CTCAE v 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. WBC: White blood cells.

Time frame:
Baseline (Day 1) and up to approximately 194 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Anemia, Increase to G1023
Anemia, Increase to G2324
Anemia, Increase to G3212
Anemia, Increase to G4000
Hemoglobin increased, Increase to G1100
Hemoglobin increased, Increase to G2000
Hemoglobin increased, Increase to G3000
Hemoglobin increased, Increase to G4000
Lymphocyte decreased, Increase to G1002
Lymphocyte decreased, Increase to G2242
Lymphocyte decreased, Increase to G3212
Lymphocyte decreased, Increase to G4102
Lymphocyte increased, Increase to G1100
Lymphocyte increased, Increase to G2211
Lymphocyte increased, Increase to G3000
Lymphocyte increased, Increase to G4001
Neutrophil decreased, Increase to G1001
Neutrophil decreased, Increase to G2322
Neutrophil decreased, Increase to G3010
Neutrophil decreased, Increase to G4000
Platelet decreased, Increase to G1015
Platelet decreased, Increase to G2102
Platelet decreased, Increase to G3222
Platelet decreased, Increase to G4200
Leukocytosis, Increase to G1000
Leukocytosis, Increase to G2000
Leukocytosis, Increase to G3000
Leukocytosis, Increase to G4000
WBC decreased, Increase to G1021
WBC decreased, Increase to G2214
WBC decreased, Increase to G3200
WBC decreased, Increase to G4000
PrimaryDE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline

Blood samples were collected for the analysis of chemistry parameters. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. BLD : Blood lactate dehydrogenase, CPK: Creatine Kinase.

Time frame:
Baseline (Day 1) and up to approximately 194 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Hypoglycemia, Increase to G1011
Hypoglycemia, Increase to G2000
Hypoglycemia, Increase to G3000
Hypoglycemia, Increase to G4000
Hypoalbuminemia, Increase to G1122
Hypoalbuminemia, Increase to G2102
Hypoalbuminemia, Increase to G3000
Hypoalbuminemia, Increase to G4000
CPK increased, Increase to G1011
CPK increased, Increase to G2001
CPK increased, Increase to G3000
CPK increased, Increase to G4001
Hyperkalemia, Increase to G1021
Hyperkalemia, Increase to G2001
Hyperkalemia, Increase to G3000
Hyperkalemia, Increase to G4000
BLD increased, Increase to G1326
BLD increased, Increase to G2000
BLD increased, Increase to G3000
BLD increased, Increase to G4000
Hypermagnesemia, Increase to G1012
Hypermagnesemia, Increase to G2000
Hypermagnesemia, Increase to G3000
Hypermagnesemia, Increase to G4000
Hypomagnesemia, Increase to G1311
Hypomagnesemia, Increase to G2000
Hypomagnesemia, Increase to G3000
Hypomagnesemia, Increase to G4000
Hypernatremia, Increase to G1000
Hypernatremia, Increase to G2000
Hypernatremia, Increase to G3001
Hypernatremia, Increase to G4000
Hypercalcemia, Increase to G1121
Hypercalcemia, Increase to G2001
Hypercalcemia, Increase to G3010
Hypercalcemia, Increase to G4000
Hypocalcemia, Increase to G1242
Hypocalcemia, Increase to G2000
Hypocalcemia, Increase to G3000
Hypocalcemia, Increase to G4000
Chronic Kidney Disease, Increase to G1001
Chronic Kidney Disease, Increase to G2134
Chronic Kidney Disease, Increase to G3000
Chronic Kidney Disease, Increase to G4000
PrimaryCohort Expansion (CE) Phase: Overall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Overall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 194 weeks
Reported as:
Number · Percentage of Participants
DE Phase: Overall Response Rate (ORR)
Percentage of Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
DE Phase: Overall Response Rate (ORR)20 (2.5 to 55.6)30 (6.7 to 65.2)30 (6.7 to 65.2)
SecondaryCE Phase: Clinical Benefit Rate (CBR)

Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)

Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] were assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 194 weeks
Reported as:
Number · Percentage of Participants
DE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)
Percentage of Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Stringent Complete Response (sCR)0020
Complete Response (CR)10010
Very Good Partial Response (VGPR)1000
Partial Response (PR)0300
SecondaryCE Phase: Percentage of Participants Achieving SCR, CR, VGPR and PR

Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] was assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.

Time frame:
Predose (PD), end of infusion (EOI), and 2-hour and 24-hour postdose on Cycle 1 Day 1; predose on C1D8, C1D15 and C1D22, anytime samples on C1D8 and C1D22; predose and EOI on Day 1 of Cycles 2, 4, 6, 9 and 12; and end of treatment (~194 weeks).
Reported as:
Mean · Nanogram/ millilitre (ng/mL)
DE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)
Nanogram/ millilitre (ng/mL)1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
CYCLE 1 DAY 1, PRE-DOSE1820.0 ± 5755.354022.2 ± 12066.670.0 ± 0.00
CYCLE 1 DAY 1, END OF INFUSION41880.0 ± 22286.2130588.9 ± 7258.5241230.0 ± 6797.56
CYCLE 1 DAY 1, 2 HOURS33920.0 ± 8211.0829490.0 ± 7515.9843770.0 ± 5907.44
CYCLE 1 DAY 1, 24 HOURS25100.0 ± 11220.8519350.0 ± 5464.4334544.4 ± 12441.78
CYCLE 1 DAY 8, PRE-DOSE4635.0 ± 1552.774790.0 ± 1335.477250.0 ± 2129.57
CYCLE 1 DAY 8, ANYTIME SAMPLE8210.0 ± NA——
CYCLE 1 DAY 15, PRE-DOSE3410.0 ± 1265.352216.3 ± 958.112988.9 ± 561.10
CYCLE 1 DAY 22, PRE-DOSE2785.0 ± 1516.581348.1 ± 775.551932.2 ± 319.13
CYCLE 1 DAY 22, ANYTIME SAMPLE——1460.0 ± NA
CYCLE 2 DAY 1, PRE-DOSE1217.9 ± 935.530.0 ± 0.0090.7 ± 222.09
CYCLE 2 DAY 1, END OF INFUSION42587.5 ± 24069.3937387.5 ± 8927.0842614.3 ± 13248.32
CYCLE 4 DAY 1, PRE-DOSE1516.7 ± 1355.520.0 ± 0.00569.2 ± 721.04
CYCLE 4 DAY 1, END OF INFUSION29456.7 ± 22500.1532850.0 ± 8414.5732566.7 ± 11944.65
CYCLE 6 DAY 1, PRE-DOSE1343.3 ± 1455.690.0 ± NA1001.8 ± 817.23
CYCLE 6 DAY 1, END OF INFUSION35733.3 ± 20713.8437400.0 ± NA31725.0 ± 18434.28
CYCLE 9 DAY 1, PRE-DOSE595.0 ± 841.46—705.0 ± 997.02
CYCLE 9 DAY 1, END OF INFUSION23250.0 ± 8131.73—31500.0 ± 2687.01
CYCLE 12 DAY 1, PRE-DOSE——606.0 ± NA
CYCLE 12 DAY 1, END OF INFUSION——52400.0 ± NA
END OF TREATMENT (~ 194weeks)2211.0 ± 1654.482566.1 ± 5976.041312.7 ± 1965.46
SecondaryCE Phase: Plasma Concentration of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)

Blood samples were to be collected for PK analysis of Belantamab Mafodotin Antibody-Drug Conjugate (ADC).

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody

Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.

Time frame:
Predose, end of infusion (EOI), and 2-hour and 24-hour on Cycle 1 Day 1; predose and anytime samples on Cycle 1 Days 8 and 22; predose on Cycle 1 Day 15; predose and EOI on Day 1 of Cycles 2, 4, 6, 9, and 12; and end of treatment (~194 weeks).
Reported as:
Mean · Nanogram/ millilitre (ng/mL)
DE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody
Nanogram/ millilitre (ng/mL)1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
CYCLE 1 DAY 1, PRE-DOSE1485.7 ± 3930.836257.1 ± 16554.840.0 ± 0.00
CYCLE 1 DAY 1, END OF INFUSION37630.0 ± 12088.2030522.2 ± 9544.2139220.0 ± 12263.66
CYCLE 1 DAY 1, 2 HOURS36620.0 ± 11797.7228860.0 ± 12571.0637160.0 ± 12550.45
CYCLE 1 DAY 1, 24 HOURS27633.3 ± 12155.4522537.5 ± 10444.1328122.2 ± 7035.05
CYCLE 1 DAY 8, PRE-DOSE8268.3 ± 3033.698102.5 ± 2232.9010854.4 ± 3857.33
CYCLE 1 DAY 8, ANYTIME SAMPLE19200.0 ± NA——
CYCLE 1 DAY 15, PRE-DOSE7934.3 ± 3718.865600.0 ± 2818.828818.9 ± 2204.73
CYCLE 1 DAY 22, PRE-DOSE7168.3 ± 3151.223701.3 ± 1999.535627.8 ± 1211.40
CYCLE 1 DAY 22, ANYTIME SAMPLE——5150.0 ± NA
CYCLE 2 DAY 1, PRE-DOSE3488.8 ± 2152.26719.6 ± 811.621175.2 ± 557.36
CYCLE 2 DAY 1, END OF INFUSION37287.5 ± 13044.9236112.5 ± 11768.9041871.4 ± 21465.61
CYCLE 4 DAY 1, PRE-DOSE4080.0 ± 1967.310.0 ± 0.002731.2 ± 1657.96
CYCLE 4 DAY 1, END OF INFUSION29370.0 ± 19920.7124650.0 ± 1767.7735833.3 ± 16467.87
CYCLE 6 DAY 1, PRE-DOSE3673.3 ± 1639.71647.0 ± NA3835.0 ± 2787.04
CYCLE 6 DAY 1, END OF INFUSION33633.3 ± 15669.1828300.0 ± NA33225.0 ± 20486.15
CYCLE 9 DAY 1, PRE-DOSE2495.0 ± 1492.00—3875.0 ± 4037.58
CYCLE 9 DAY 1, END OF INFUSION26350.0 ± 18031.22—31050.0 ± 18314.07
CYCLE 12 DAY 1, PRE-DOSE——1450.0 ± NA
CYCLE 12 DAY 1, END OF INFUSION——24400.0 ± NA
END OF TREATMENT (~194 weeks)5191.4 ± 3742.273536.7 ± 5112.313063.3 ± 3509.67
SecondaryCE Phase: Plasma Concentration of Belantamab Mafodotin Plasma Total Antibody

Blood samples were to be collected for PK analysis of Belantamab mafodotin plasma total antibody.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Plasma Concentration of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).

Time frame:
Predose, end of infusion (EOI), and 2-hour and 24-hour postdose on Cycle 1 Day 1; predose on Cycle 1 Days 8, 15 and 22, anytime samples on C1D8 and C1D22 ; predose and EOI on Day 1 of Cycles 2, 4, 6, 9 and 12; and end of treatment (~194 weeks).
Reported as:
Mean · Picogram / millilitre (pg/mL)
DE Phase: Plasma Concentration of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)
Picogram / millilitre (pg/mL)1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
CYCLE 1 DAY 1, PRE-DOSE137.78 ± 413.33336.78 ± 110.3330.00 ± 0.000
CYCLE 1 DAY 1, END OF INFUSION602.56 ± 589.458433.89 ± 564.095772.90 ± 758.482
CYCLE 1 DAY 1, 2 HOURS660.78 ± 592.060381.34 ± 497.727689.70 ± 541.778
CYCLE 1 DAY 1, 24 HOURS796.67 ± 277.976809.50 ± 550.0831075.56 ± 1111.764
CYCLE 1 DAY 8, PRE-DOSE137.62 ± 59.834124.53 ± 52.716198.80 ± 88.967
CYCLE 1 DAY 8, ANYTIME SAMPLE125.00 ± NA——
CYCLE 1 DAY 15, PRE-DOSE0.00 ± 0.0000.00 ± 0.00013.98 ± 25.948
CYCLE 1 DAY 22, PRE-DOSE0.00 ± 0.0000.00 ± 0.0000.00 ± 0.000
CYCLE 1 DAY 22, ANYTIME SAMPLE——0.00 ± NA
CYCLE 2 DAY 1, PRE-DOSE0.00 ± 0.0000.00 ± 0.0000.00 ± 0.000
CYCLE 2 DAY 1, END OF INFUSION480.13 ± 494.302372.25 ± 239.605319.86 ± 153.035
CYCLE 4 DAY 1, PRE-DOSE0.00 ± 0.0000.00 ± 0.0000.00 ± 0.000
CYCLE 4 DAY 1, END OF INFUSION1128.67 ± 1622.007548.00 ± 550.129393.83 ± 408.512
CYCLE 6 DAY 1, PRE-DOSE0.00 ± 0.0000.00 ± NA0.00 ± 0.000
CYCLE 6 DAY 1, END OF INFUSION677.67 ± 773.029194.00 ± NA231.00 ± 100.416
CYCLE 9 DAY 1, PRE-DOSE0.00 ± 0.000—0.00 ± 0.000
CYCLE 9 DAY 1, END OF INFUSION242.95 ± 229.173—277.00 ± 190.919
CYCLE 12 DAY 1, PRE-DOSE——0.00 ± NA
CYCLE 12 DAY 1, END OF INFUSION——258.00 ± NA
END OF TREATMENT (~194 weeks)19.79 ± 37.17443.50 ± 123.03719.67 ± 48.173
SecondaryCE Phase: Plasma Concentration of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

Blood samples were to be collected for PK analysis of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Isatuximab Concentration When Administered in Combination With Belantamab Mafodotin

Blood samples were collected for PK analysis of Isatuximab when administered intravenously in combination with belantamab mafodotin.

Time frame:
Predose on Cycle (C)1 Day (D)1, D8, D15 and D22; predose on C2D1 and C2D15; predose on C3D1 and C3D15; predose on C4D1 and C4D15; predose on C5D1, C6D1, C7D1, C8D1, C9D1 and C10D1; and end of treatment (~194 weeks).
Reported as:
Mean · ng/mL
DE Phase: Isatuximab Concentration When Administered in Combination With Belantamab Mafodotin
ng/mL1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
CYCLE 1 DAY 1, PRE-DOSE0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
CYCLE 1 DAY 8, PRE-DOSE92.757 ± 38.467883.566 ± 35.0687106.944 ± 16.3712
CYCLE 1 DAY 15, PRE-DOSE187.171 ± 99.5832181.600 ± 72.2766223.956 ± 80.4607
CYCLE 1 DAY 22, PRE-DOSE306.243 ± 271.6850238.788 ± 94.5186305.444 ± 87.6985
CYCLE 2 DAY 1, PRE-DOSE297.850 ± 143.1613235.865 ± 206.5359346.957 ± 182.0090
CYCLE 2 DAY 15, PRE-DOSE368.400 ± 180.6967267.740 ± 158.6950260.250 ± 104.3532
CYCLE 3 DAY 1, PRE-DOSE478.250 ± 258.3001249.040 ± 195.5971388.500 ± 144.9341
CYCLE 3 DAY 15, PRE-DOSE423.250 ± 158.3759309.000 ± 49.4975413.600 ± 197.7291
CYCLE 4 DAY 1, PRE-DOSE555.333 ± 471.7121162.580 ± 216.9686460.333 ± 108.4706
CYCLE 4 DAY 15, PRE-DOSE459.333 ± 337.5001179.900 ± 219.3445446.600 ± 115.0795
CYCLE 5 DAY 1, PRE-DOSE403.333 ± 224.0855171.700 ± 216.7989440.400 ± 136.8843
CYCLE 6 DAY 1, PRE-DOSE351.000 ± 228.0592420.000 ± NA468.750 ± 45.1101
CYCLE 7 DAY 1, PRE-DOSE649.000 ± NA304.000 ± NA503.000 ± 54.9121
CYCLE 8 DAY 1, PRE-DOSE665.000 ± NA121.000 ± NA447.250 ± 87.2788
CYCLE 9 DAY 1, PRE-DOSE493.000 ± 113.1371—449.000 ± 114.5513
CYCLE 10 DAY 1, PRE-DOSE413.000 ± NA—458.000 ± 114.5513
END OF TREATMENT (~194 weeks)289.490 ± 212.0699202.613 ± 200.3017276.717 ± 202.2553
SecondaryCE Phase: Isatuximab Concentration When Administered in Combination With Belantamab Mafodotin

Blood samples were planned to be collected for PK analysis of isatuximab when administered intravenously in combination with belantamab mafodotin.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to approximately 194 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin010
SecondaryCE Phase: Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Titer of ADAs Against Belantamab Mafodotin

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to approximately 194 weeks
Reported as:
Median · Titers
DE Phase: Titer of ADAs Against Belantamab Mafodotin
Titers1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
DE Phase: Titer of ADAs Against Belantamab Mafodotin—400.0 (NA to NA)—
SecondaryCE Phase: Titer of ADAs Against Belantamab Mafodotin

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Adverse Events of Special Interest (AESI)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI, whether serious or non serious were collected.

Time frame:
Up to approximately 194 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)878
SecondaryCE Phase: Number of Participants With AESI

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI, whether serious or non serious, were to be collected.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade

The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade v 5.0.

Time frame:
Up to approximately 194 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade
Participants1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Grade 1343
Grade 2101
Grade 3000
Grade 4000
Grade 5000
SecondaryCE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade

The corneal events were planned to be graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results were to be presented for number of participants with any corneal events by maximum grade as per CTCAE grade v5.0.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Progression-free Survival (PFS)

PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Duration of Response (DoR)

DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Time to Response (TTR)

TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Overall Survival (OS)

OS is defined as the time from randomization until death due to any cause.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With AEs and SAEs

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With AEs Leading to Discontinuation

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to discontinuation were to be evaluated.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With Dose Reduction or Delay

Number of participants with dose reduction or delay were to be evaluated.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters

Blood samples were to be collected for the analysis of hematology parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3: severe or medically significant; Grade 4 (G4): Life-threatening consequences; Grade 5 (G5): Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters

Blood samples were to be collected for the analysis of chemistry parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. G1: mild; G2: moderate; G3: severe or medically significant; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

Time frame:
Up to approximately 194 weeks

No measurements were reported for this outcome.

Adverse events

Collected over All cause mortality, Non- Serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs) were collected up to approximately 194 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab6/10 (60%)1/10 (10%)10/10 (100%)
1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab3/10 (30%)3/10 (30%)9/10 (90%)
1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab3/10 (30%)3/10 (30%)10/10 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
Event1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Atrial fibrillationCardiac disorders0/100/101/10
Myocardial ischaemiaCardiac disorders0/100/101/10
Sinus bradycardiaCardiac disorders0/100/101/10
Bacteroides bacteraemiaInfections and infestations0/100/101/10
BronchitisInfections and infestations0/100/101/10
COVID-19Infections and infestations0/100/101/10
Device related infectionInfections and infestations0/100/101/10
Gastroenteritis salmonellaInfections and infestations0/101/100/10
PneumoniaInfections and infestations0/101/101/10
Pneumonia bacterialInfections and infestations0/100/101/10
Most frequent other events
Showing 10 of 98
Most frequent other events
Event1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab
Vision blurredEye disorders6/104/102/10
AnaemiaBlood and lymphatic system disorders4/102/103/10
ThrombocytopeniaBlood and lymphatic system disorders3/101/104/10
Dry eyeEye disorders3/104/103/10
DiarrhoeaGastrointestinal disorders0/102/104/10
Back painMusculoskeletal and connective tissue disorders4/100/101/10
Foreign body sensation in eyesEye disorders2/102/103/10
PhotophobiaEye disorders3/101/102/10
Platelet count decreasedInvestigations3/102/102/10
HypokalaemiaMetabolism and nutrition disorders3/101/101/10

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + IsatuximabTotal
Mean64.9 ± 8.5270.3 ± 8.7669.1 ± 10.1468.1 ± 9.15
Sex: Female, Male
Sex: Female, Male(Participants)1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + IsatuximabTotal
Female57517
Male53513
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab1.9 mg/kg Belantamab Mafodotin (Q8W) + IsatuximabTotal
American Indian or Alaska Native0101
Asian1124
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White87823
More than one race0000
Unknown or Not Reported0000
08

Study locations

19 sites
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Grand Rapids, Michigan 49546, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
  • GSK Investigational Site
    Salvador, Estado de Bahia 41253-190, Brazil
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Villejuif, 94805, France
  • GSK Investigational Site
    Athens, 11528, Greece
  • GSK Investigational Site
    Mexico City, 01330, Mexico
  • GSK Investigational Site
    Oslo, 0450, Norway
  • GSK Investigational Site
    Seoul, 06351, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Ulsan, 44033, South Korea
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Pozuelo de AlarcOn Madr, 28223, Spain
  • GSK Investigational Site
    Falun, SE-791 82, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2025, 44 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 44 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 15, 2025
StartActual
Jul 29, 2021
Primary completionActual
Apr 17, 2025
CompletionEst.
Mar 11, 2027
Results first posted
Jun 25, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07217184
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Jul 29, 2021
Primary completion
Apr 17, 2025
Completion
Mar 11, 2027 (estimated)
Results posted
Jun 25, 2026
Last update
Jun 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab mafodotin · Isatuximab

Start the discussion